Emergency Medicine

HIV / AIDS

Medical News

Primary Care

Surgery

Home » Medical News

Ambit Biosciences And Astellas Enter Strategic Partnership To Research, Develop And Commercialize FLT3 Kinase Inhibitors In Multiple Indications

Submitted by MedicalReplies on Saturday, 19 December 2009No Comment

Ambit Biosciences Corporation and Astellas Pharma Inc. announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.

Excerpt from:
Ambit Biosciences And Astellas Enter Strategic Partnership To Research, Develop And Commercialize FLT3 Kinase Inhibitors In Multiple Indications

You may also like:

Leave your response!

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.

*
To prove you're a person (not a spam script), type the security word shown in the picture.
Anti-spam image